Does the registry speak your language? A case study of the Global Angelman Syndrome Registry

Megan Tones, Nikolajs Zeps, Yvette Wyborn, Adam Smith, Roberto A Barrero, Helen Heussler, Meagan Cross, James McGree, Matthew Bellgard, Megan Tones, Nikolajs Zeps, Yvette Wyborn, Adam Smith, Roberto A Barrero, Helen Heussler, Meagan Cross, James McGree, Matthew Bellgard

Abstract

Global disease registries are critical to capturing common patient related information on rare illnesses, allowing patients and their families to provide information about their condition in a safe, accessible, and engaging manner that enables researchers to undertake critical research aimed at improving outcomes. Typically, English is the default language of choice for these global digital health platforms. Unfortunately, language barriers can significantly inhibit participation from non-English speaking participants. In addition, there is potential for compromises in data quality and completeness. In contrast, multinational commercial entities provide access to their websites in the local language of the country they are operating in, and often provide multiple options reflecting ethnic diversity. This paper presents a case study of how the Global Angelman Syndrome Registry (GASR) has used a novel approach to enable multiple language translations for its website. Using a "semi-automated language translation" approach, the GASR, which was originally launched in English in September 2016, is now available in several other languages. In 2020, the GASR adopted a novel approach using crowd-sourcing and machine translation tools leading to the availability of the GASR in Spanish, Traditional Chinese, Italian, and Hindi. As a result, enrolments increased by 124% percent for Spain, 67% percent for Latin America, 46% percent for Asia, 24% for Italy, and 43% for India. We describe our approach here, which we believe presents an opportunity for cost-effective and timely translations responsive to changes to the registry and helps build and maintain engagement with global disease communities.

Keywords: Disease Registry; Equity diversity and inclusion; Language translation; Patient reported outcomes.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).

Figures

Fig. 1
Fig. 1
Growth in registry participation pre and post translations

References

    1. Foundation for Angelman Syndrome Therapeutics [FAST]. What is Angelman Syndrome. Accessed October 4, 2022.
    1. Rare disease day. Updated 2023. Accessed January 25, 2023.
    1. European Commission. Updated 2023. Accessed January 25, 2023.
    1. Agency for Healthcare Research and Quality ([AHRQ], 2020). Registries for Evaluating Patient Outcomes. Published [Date]. Accessed [Date]. URL
    1. National Centre for Advancing Translational Sciences [NCATS]. Rare Diseases Registry Program. (RaDaR). Accessed January 25, 2023.
    1. Pasquini TLS, Mesfin M, Raskin J. HI Global Registry 2022 Annual Report. Published [Date]. Accessed January 27, 2023.
    1. Bohonowych J, Miller J, McCandless SE, Strong TV. The global Prader-Willi syndrome registry: development, launch, and early demographics. Genes (Basel). 2019;10(9):713. doi: 10.3390/genes10090713.
    1. Forrest C, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet. 2011;377(9771):1057–1059. doi: 10.1016/S0140-6736(10)60680-0.
    1. Krey I, Heine C, Frömming M, Herrmann J, Møller RS, Weckhuysen S, Courage C, Beblo S, Syrbe S, Lemke JR. The Angelman syndrome online registry—a multilingual approach to support global research. Eur J Med Genet. 2021;64(12):104349. doi: 10.1016/j.ejmg.2021.104349.
    1. Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol. 2015;68(4):435–441. doi: 10.1016/j.jclinepi.2014.11.021.
    1. Anastasiou D, Gupta R. Comparison of crowdsourcing translation with machine translation. J Inf Sci. 2011;37(6):63–69. doi: 10.1177/0165551511418760.
    1. Qun L, Xiaojun Z. Machine translation. In: Chan S, editor. The Routledge encyclopedia of translation technology. Abingdon: Routledge; 2015. pp. 105–119.
    1. O’Hagan M. Computer-aided translation (CAT) In: Baker M, Saldanha C, editors. Routledge encyclopedia of translation studies. Abingdon: Routledge; 2009. pp. 48–51.
    1. Wazny K. Crowdsourcing” ten years in: a review. J Glob Health. 2017;7(2):020602. doi: 10.7189/jogh.07.020602.
    1. Bassi H, Lee CJ, Misener L, Johnson AM. Exploring the characteristics of crowdsourcing: an online observational study. J Inf Sci. 2020;46(3):291–312. doi: 10.1177/0165551519828626.
    1. Behmen D, Marušić A, Puljak L. Capacity building for knowledge translation: a survey about the characteristics and motivation of volunteer translators of Cochrane plain language summaries. J Evid Based Med. 2019;12(2):147–154. doi: 10.1111/jebm.12345.
    1. Blohm I, Zogaj S, Bretschneider U, Leimeister JM. How to manage crowdsourcing platforms effectively. Calif Manag Rev. 2018;60(2):122–149. doi: 10.1177/000812561773825.
    1. Tones M, Cross M, Simons C, Napier KR, Hunter A, Bellgard MI, Heussler H. Research protocol: the initiation, design and establishment of the Global Angelman Syndrome Registry. J Intellect Disabil Res. 2018;62(5):431–443. doi: 10.1111/jir.12482.
    1. Hammond E, Youngs L, Bellgard M, Dawkins HSP. 33 Australasian neuromuscular disease registry (conference abstract) Neuromuscul Disorders. 2012;22(9–10):881. doi: 10.1016/j.nmd.2012.06.258.
    1. Bellgard M, Macgregor A, Janon F, et al. A modular approach to disease registry design: successful adoption of an internet-based rare disease registry. Hum Mutat. 2012;33(10):E2356–E2366. doi: 10.1002/humu.22154.
    1. Bellgard M, Beroud C, Parkinson K, et al. Dispelling myths about rare disease registry system development. Source Code for Biol Med. 2013;9(1):1–7. doi: 10.1186/1751-0473-9-4.
    1. Bellgard M, Render L, Radochonski M, Hunter A. Second generation registry framework. Source Code for Biol Med. 2014;9(14):1–6. doi: 10.1186/1751-0473-9-14.
    1. Bladen C, Salgado D, Monges S, et al. The TREAT-NMD DMD Global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395–402. doi: 10.1002/humu.22758.
    1. Bellgard M, Walker C, Napier K, et al. Design of the familial hypercholesterolaemia Australasia network registry: creating opportunities for greater international collaboration. J Atheroscler Thromb. 2017;24(10):1075–1084. doi: 10.5551/jat.37507.
    1. Napier K, Pang J, Lamont L, et al. A web-based registry for familial hypercholesterolaemia. Heart Lung Circ. 2017;26(6):635–639. doi: 10.1016/j.hlc.2016.10.019.
    1. Koeks Z, Bladen C, Salgado D, et al. Clinical outcomes in duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4(4):293–306. doi: 10.3233/JND-170280.
    1. Napier K, Tones M, Simons C, et al. A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry. Orphanet J Rare Dis. 2017;12(134):1–5. doi: 10.1186/s13023-017-0686-1.
    1. Bellgard M, Napier K, Bittles A, et al. Design of a framework for the deployment of collaborative independent rare disease-centric registries: gaucher disease registry model. Blood Cells Mol Dis. 2018;68:232–238. doi: 10.1016/j.bcmd.2017.01.013.
    1. Ng D, Hooper A, Bellgard M, Burnett J. The role of patient registries for rare genetic lipid disorders. Curr Opin Lipidol. 2018;29(2):156–162. doi: 10.1097/MOL.0000000000000485.
    1. Schultz A, Marsh JA, Saville BR, et al. Trial refresh: a case for an adaptive platform trial for pulmonary exacerbations of cystic fibrosis. Front Pharmacol. 2019;28(10):301. doi: 10.3389/fphar.2019.00301.PMID:30983998;PMCID:PMC6447696.
    1. Napier KR, Hooper AJ, Ng DM, et al. Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology. 2020;52(4):447–452. doi: 10.1016/j.pathol.2020.02.002.
    1. Ramsay J, Marsh J, Pedrana A, et al. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C. BMC Infect Dis. 2020;20:802. doi: 10.1186/s12879-020-05531-4.
    1. Graham C, Molster C, Baynam G, et al. Current trends in biobanking for rare diseases: a review. J Biorepos Sci Appl Med. 2014;2:49–61. doi: 10.2147/BSAM.S46707.
    1. Vucic S, Wray N, Henders A, et al. MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5–6):321–328. doi: 10.1080/21678421.2021.1980889.
    1. Bellgard MI, Snelling T, McGree JM. RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework. Orphanet J Rare Dis. 2019 doi: 10.1186/s13023-019-1139-9.
    1. Leader G, Whelan S, Chonaill NN, et al. Association between early and current gastro-intestinal symptoms and co-morbidities in children and adolescents with Angelman syndrome. J Intellect Disabil Res. 2022;66(11):865–879. doi: 10.1111/jir.12975.
    1. Leader G, Gilligan R, Whelan S, et al. Relationships between challenging behavior and gastrointestinal symptoms, sleep problems, and internalizing and externalizing symptoms in children and adolescents with Angelman syndrome. Res Dev Disabil. 2022;128(104293):1–13. doi: 10.1016/j.ridd.2022.104293.
    1. Roche L, Tones M, Cross M, et al. An overview of the adaptive behaviour profile in young children with Angelman Syndrome: insights from the global Angelman Syndrome Registry. Adv Neurodev Disord. 2022;6:442–455. doi: 10.1007/s41252-022-00278-2.
    1. Roche L, Tones M, Williams MG, et al. Caregivers report on the pathway to a formal diagnosis of angelman syndrome: a comparison across genetic etiologies within the Global Angelman Syndrome Registry. Adv Neurodev Disord. 2021;5:193–203. doi: 10.1007/s41252-021-00195-w.
    1. Crowdin Enterprise (n.d.). . Accessed 20 February 2023

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren